B. Metzler Seel. Sohn & Co. Holding Ag Cytokinetics Inc Transaction History
B. Metzler Seel. Sohn & Co. Holding Ag
- $10.1 Trillion
- Q3 2024
A detailed history of B. Metzler Seel. Sohn & Co. Holding Ag transactions in Cytokinetics Inc stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Holding Ag holds 4,698 shares of CYTK stock, worth $245,329. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,698Holding current value
$245,329% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CYTK
# of Institutions
410Shares Held
125MCall Options Held
4.6MPut Options Held
2.43M-
Black Rock Inc. New York, NY14.7MShares$766 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$614 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.69MShares$506 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA7.77MShares$406 Million0.07% of portfolio
-
State Street Corp Boston, MA6.46MShares$337 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.92B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...